> > > 【スタッフ紹介】久保 寿夫

【スタッフ紹介】久保 寿夫

【卒業年】 平成14年(2002年)

【学位取得年月】 平成25年3月(2013年)

【専門領域】
腫瘍内科学,呼吸器内科学

【資格】
総合内科専門医(日本内科学会),がん薬物療法専門医(日本臨床腫瘍学会),呼吸器専門医(日本呼吸器学会),がん治療認定医(がん治療認定医機構)

【所属学会】
日本内科学会,日本臨床腫瘍学会,日本癌治療学会,日本癌学会,日本呼吸器学会,日本肺癌学会,日本呼吸器内視鏡学会,日本緩和医療学会

【略歴】
2002年4月 岡山大学医学部附属病院 第二内科 研修医
2002年6月 国立病院機構岡山医療センター 研修医
2004年6月 住友別子病院 内科専攻医
2006年6月 岡山大学医学部・歯学部付属病院 呼吸器内科 医員
2010年6月 中国中央病院 呼吸器内科 医長
2013年9月 岡山大学病院 呼吸器・アレルギー内科 助教
2013年12月 岡山大学病院 腫瘍センター 助教

【一言】
みなさまに最適な医療が提供できるよう、努力していきたいと思います。

【研究テーマ】
・小細胞肺癌における癌幹細胞に関する研究
・EGFR遺伝子変異陽性肺癌におけるVEGFR阻害薬の効果に関する研究
・肺癌化学療法に関する臨床研究(geriatric oncologyなど)

【主な業績】

最近の業績(Pubmedへのリンク)

1. Optimal method for quantitative detection of plasma EGFR T790M mutation using droplet digital PCR system. Suzawa K, Yamamoto H, Ohashi K, Hashida S, Tomida S, Kubo T, Maki Y, Soh J, Tsukuda K, Kiura K, Miyoshi S, Toyooka S. Oncol Rep. 2017;37:3100-6.

2. Triplet therapy with afatinib, cetuximab, and bevacizumab induces deep remission in lung cancer cells harboring EGFR T790M in vivo. Kudo K, Ohashi K, Makimoto G, Higo H, Kato Y, Kayatani H, Kurata Y, Takami Y, Minami D, Ninomiya T, Kubo T, Ichihara E, Sato A, Hotta K, Yoshino T, Tanimoto M, Kiura K. Mol Oncol. 2017 [Epub ahead of print]

3. Discomfort during bronchoscopy performed after endobronchial intubation with fentanyl and midazolam: a prospective study. Minami D, Takigawa N, Kano H, Ninomiya T, Kubo T, Ichihara E, Ohashi K, Sato A, Hotta K, Tabata M, Tanimoto M, Kiura K. Jpn J Clin Oncol. 2017;47:434-7.

4. Three-Arm Randomized Trial of Sodium Alginate for Preventing Radiation-Induced Esophagitis in Locally Advanced Non-Small Cell Lung Cancer Receiving Concurrent Chemoradiotherapy: The OLCSG1401 Study Protocol. Ninomiya K, Ichihara E, Hotta K, Sone N, Murakami T, Harada D, Oze I, Kubo T, Tanaka H, Kuyama S, Kishino D, Bessho A, Harita S, Katsui K, Tanimoto M, Kiura K. Clin Lung Cancer. 2017 Mar;18:245-9.

5. Potential influence of being overweight on the development of hepatic dysfunction in Japanese patients with EGFR-mutated non-small cell lung cancer undergoing gefitinib monotherapy: the Okayama Lung Cancer Study Group experience. Oda N, Hotta K, Yoshioka H, Kudo K, Ichihara E, Kato Y, Ninomiya K, Minami D, Ninomiya T, Kubo T, Ohashi K, Sato A, Takigawa N, Tabata M, Tanimoto M, Kiura K. Cancer Chemother Pharmacol. 2016;78:941-7.

6. Protocol Design for the Bench to Bed Trial in Alectinib-Refractory Non-Small-Cell Lung Cancer Patients Harboring the EML4-ALK Fusion Gene (ALRIGHT/OLCSG1405). Isozaki H, Hotta K, Ichihara E, Takigawa N, Ohashi K, Kubo T, Ninomiya T, Ninomiya K, Oda N, Yoshioka H, Ichikawa H, Inoue M, Takata I, Shibayama T, Kuyama S, Sugimoto K, Harada D, Harita S, Sendo T, Tanimoto M, Kiura K. Clin Lung Cancer. 2016;17:602-5.

7. Effect of Vandetanib on Lung Tumorigenesis in Transgenic Mice Carrying an Activating Egfr Gene Mutation. Osawa M, Ohashi K, Kubo T, Ichikawa E, Takata S, Takigawa N, Takata M, Tanimoto M, Kiura K. Acta Med Okayama. 2016;70:243-53.

8. A phase II study of topotecan and cisplatin with sequential thoracic radiotherapy in elderly patients with small-cell lung cancer: Okayama Lung Cancer Study Group 0102. Kubo T, Fujiwara K, Hotta K, Okada T, Kuyama S, Harita S, Ninomiya T, Kamei H, Hosokawa S, Bessho A, Maeda T, Kozuki T, Fujimoto N, Ninomiya K, Takemoto M, Kanazawa S, Takigawa N, Tabata M, Tanimoto M, Ueoka H, Kiura K. Cancer Chemother Pharmacol. 2016;78:769-74.

9. Safety and discomfort during bronchoscopy performed under sedation with fentanyl and midazolam: a prospective study. Minami D, Takigawa N, Watanabe H, Ninomiya T, Kubo T, Ohashi K, Sato A, Hotta K, Tabata M, Tanimoto M, Kiura K. Jpn J Clin Oncol. 2016;46:871-4.

10. Endobronchial ultrasound-guided transbronchial needle aspiration of hilar and mediastinal lymph nodes detected on 18F-fluorodeoxyglucose positron emission tomography/computed tomography. Minami D, Takigawa N, Oda N, Ninomiya T, Kubo T, Ohashi K, Sato A, Hotta K, Tabata M, Kaji M, Tanimoto M, Kiura K. Jpn J Clin Oncol. 2016;46:529-33.

11. Short-term low-volume hydration in cisplatin-based chemotherapy for patients with lung cancer: the second prospective feasibility study in the Okayama Lung Cancer Study Group Trial 1201. Ninomiya K, Hotta K, Hisamoto-Sato A, Ichihara E, Gotoda H, Morichika D, Tamura T, Kayatani H, Minami D, Kubo T, Tabata M, Tanimoto M, Kiura K. Int J Clin Oncol. 2016;21:81-7.

12. Downregulation of TBXAS1 in an iron-induced malignant mesothelioma model. Minami D, Takigawa N, Kato Y, Kudo K, Isozaki H, Hashida S, Harada D, Ochi N, Fujii M, Kubo T, Ohashi K, Sato A, Tanaka T, Hotta K, Tabata M, Toyooka S, Tanimoto M, Kiura K.Cancer Sci. 2015;106:1296-302.

13. Programmed cell death protein 1 and programmed death-ligand 1 are expressed on the surface of some small-cell lung cancer lines. Yamane H, Isozaki H, Takeyama M, Ochi N, Kudo K, Honda Y, Yamagishi T, Kubo T, Kiura K, Takigawa N. Am J Cancer Res. 2015;5:1553-7.

14. Endobronchial ultrasound-guided transbronchial biopsy with or without a guide sheath for diagnosis of lung Cancer. Minami D, Takigawa N, Morichika D, Kubo T, Ohashi K, Sato A, Hotta K, Tabata M, Tanimoto M, Kiura K. Respir Investig. 2015;53:93-7.

15. Magnitude of the benefit of progression-free survival as a potential surrogate marker in phase 3 trials assessing targeted agents in molecularly selected patients with advanced non-small cell lung cancer: systematic review. Hotta K, Kato Y, Leighl N, Takigawa N, Gaafar RM, Kayatani H, Hirata T, Ohashi K, Kubo T, Tabata M, Tanimoto M, Kiura K. PLoS One. 2015;10:e0121211.

16. Phase II trial of gefitinib in combination with bevacizumab as first-line therapy for advanced non-small cell lung cancer with activating EGFR gene mutations: the Okayama Lung Cancer Study Group Trial 1001. Ichihara E, Hotta K, Nogami N, Kuyama S, Kishino D, Fujii M, Kozuki T, Tabata M, Harada D, Chikamori K, Aoe K, Ueoka H, Hosokawa S, Bessho A, Hisamoto-Sato A, Kubo T, Oze I, Takigawa N, Tanimoto M, Kiura K. J Thorac Oncol. 2015;10:486-91.

17. Cisplatin-induced hyponatremia in malignancy: comparison between brand-name and generic formulation. Ochi N, Yamane H, Hotta K, Fujii H, Isozaki H, Honda Y, Yamagishi T, Kubo T, Tanimoto M, Kiura K, Takigawa N. Drug Des Devel Ther. 2014;8:2401-8.

18. A phase II study of S-1 chemotherapy with concurrent thoracic radiotherapy in elderly patients with locally advanced non-small-cell lung cancer: The Okayama Lung Cancer Study Group Trial 0801. Aoe K, Takigawa N, Hotta K, Maeda T, Kishino D, Nogami N, Tabata M, Harita S, Okada T, Kubo T, Hosokawa S, Fujiwara K, Gemba K, Yasugi M, Kozuki T, Kato Y, Katsui K, Kanazawa S, Ueoka H, Tanimoto M, Kiura K. Eur J Cancer. 2014;50:2783-90.

19. Effect of AZD1480 in an epidermal growth factor receptor-driven lung cancer model. Murakami T, Takigawa N, Ninomiya T, Ochi N, Yasugi M, Honda Y, Kubo T, Ichihara E, Hotta K, Tanimoto M, Kiura K. Lung Cancer. 2014;83:30-6.

20. Efficacy of multimodal treatment for leptomeningeal metastases in a lung cancer harboring an EGFR mutation. Morichika D, Kubo T, Gotoda H, Tamura T, Ohashi K, Hotta K, Tabata M, Kurozumi K, Tanimoto M, Kiura K. Onco Targets Ther. 2016;9:1753-8.

21. Fatal Candida septic shock during systemic chemotherapy in lung cancer patient receiving corticosteroid replacement therapy for hypopituitarism: a case report. Morichika D, Sato-Hisamoto A, Hotta K, Takata K, Iwaki N, Uchida K, Minami D, Kubo T, Tanimoto M, Kiura K. Jpn J Clin Oncol. 2014;44:501-5.

22. Clinical characteristics of Japanese candidates for lung transplant for interstitial lung disease and risk factors for early death while on the waiting list. Higo H, Kurosaki T, Ichihara E, Kubo T, Miyoshi K, Otani S, Sugimoto S, Yamane M, Miyahara N, Kiura K, Miyoshi S, Oto T. Respir Investig. 2017 Jul;55(4):264-9.

23. 喫煙再開後の発症が疑われた肺ランゲルハンス細胞組織球症の1例.渡邉洋美,久保寿夫,田端雅弘,妹尾賢,秦雄介,木浦勝行.日本呼吸器学会雑誌. 2017;6:255-59.

24. ニボルマブ治療中にニューモシスチス肺炎を発症した肺多形癌の1例.妹尾賢,久保寿夫,狩野裕久,西井和也,田端雅弘,木浦勝行.日本呼吸器学会雑誌. 2017;6:283-6.

戻る